Amicus Therapeutics, Inc. (OQ:FOLD)

Business Focus: Biotechnology & Medical Research

Mar 23, 2020 07:00 am ET
Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the Company has proactively taken numerous measures in...
Mar 05, 2020 07:00 am ET
Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia
Amicus Therapeutics (Nasdaq: FOLD) today announced the official opening of the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia to advance its industry leading portfolio of rare disease gene therapy...
Mar 02, 2020 07:00 am ET
Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019....
Feb 26, 2020 07:00 am ET
Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 8:40 a.m. ET. A live...
Feb 19, 2020 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 2, 2020 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2019. The call will...
Feb 07, 2020 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020
Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that one oral presentation and nine posters highlighting its...
Jan 13, 2020 07:00 am ET
Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance
Amicus Therapeutics (Nasdaq: FOLD), a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today provided its full-year 2020 strategic outlook and financial guidance....
Jan 09, 2020 07:00 am ET
Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance
Amicus Therapeutics (Nasdaq: FOLD), a global, patient dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced preliminary 2019 revenue and Galafold (migalastat)...
Jan 07, 2020 07:00 am ET
Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced clinical, regulatory and manufacturing advancements...
Nov 11, 2019 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2019. The...
Oct 30, 2019 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019. The...
Oct 24, 2019 07:00 am ET
Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. The results are...
Oct 10, 2019 07:30 am ET
Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day
Amicus Therapeutics (Nasdaq: FOLD) today announced preliminary unaudited revenue for the third quarter of 2019 in advance of its Analyst Day, to be held today, October 10, 2019, in New York City at 8:30 a.m. Today’s Analyst Day will highlight the...
Oct 02, 2019 07:00 am ET
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an...
Oct 01, 2019 07:00 am ET
Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences: An oral presentation highlighting Phase 1/2 results, including cohort 4, for...
Sep 04, 2019 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell, President and Chief Operating Officer, and Jeff Castelli, Chief Portfolio Officer and Head of Gene...
Aug 08, 2019 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2019. The...
Aug 02, 2019 07:00 am ET
Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Agency of Medicines, Food and Medical Devices (ANMAT) in Argentina has granted approval for the first-in-class, oral small molecule pharmacological chaperone Galafold® (migalastat), as a...
Aug 01, 2019 06:00 am ET
Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. AWRI is conducting the...
Jul 29, 2019 07:00 am ET
Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2019. The call...
Jul 02, 2019 07:30 am ET
Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and capacity for multiple active preclinical lysosomal...
Jul 01, 2019 07:00 am ET
Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific1. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with late-stage clinical and...
Jun 13, 2019 07:30 am ET
Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership
Amicus Therapeutics (Nasdaq: FOLD) today announced two new additions to the Senior Leadership Team. Jill Weimer, PhD, a developmental neuroscientist and recognized thought leader in the field of neurologic rare disease gene therapy science, has...
Jun 04, 2019 04:01 pm ET
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 18,720,930 shares of its common stock, including 2,441,860 shares of common stock sold pursuant to...
Jun 03, 2019 07:00 am ET
Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June. Upcoming Scientific Conference: Michael C. Diem, MD, Senior Vice President of Business and Corporate...
May 30, 2019 09:00 pm ET
Amicus Therapeutics Prices Underwritten Offering of Common Stock
Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million, before...
May 29, 2019 04:14 pm ET
Amicus Therapeutics Announces Public Offering of Common Stock
Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock.  J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers...
May 29, 2019 06:30 am ET
Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration
Amicus Therapeutics (Nasdaq: FOLD) and the Perelman School of Medicine at the University of Pennsylvania (Penn) today announced a major expansion to their collaboration with rights to pursue collaborative research and development of novel gene...
May 13, 2019 05:00 pm ET
Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations.  He has...
May 10, 2019 07:00 am ET
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14,...
May 08, 2019 07:00 am ET
Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the first quarter ended March 31, 2019. The...
Apr 30, 2019 06:00 am ET
Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in mice. These data will be highlighted in a poster (Poster 82, Abstract 518)...
Apr 25, 2019 07:00 am ET
Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2019. The call will...
Apr 15, 2019 12:00 pm ET
Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting
Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene & Cell...
Mar 29, 2019 07:10 am ET
Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon — What Drives Growth in Today's Com
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five Below, Inc. (NASDAQ:FIVE), INVESCO MORTGAGE CAPITAL INC (NYSE:IVR),...
Mar 20, 2019 07:00 am ET
Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase...
Feb 28, 2019 07:00 am ET
Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the full year ended December 31, 2018. The...
Feb 26, 2019 07:00 am ET
Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
Amicus Therapeutics (Nasdaq: FOLD) today announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to world-class science that makes a meaningful...
Feb 25, 2019 04:00 am ET
U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted to Amicus a Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal...
Feb 13, 2019 07:30 am ET
New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Clovis Oncology, Inc....
Feb 12, 2019 07:00 am ET
Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2018. The call...
Feb 05, 2019 04:01 pm ET
Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme...
Jan 18, 2019 07:00 am ET
Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting its...
Jan 10, 2019 07:30 am ET
Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FedEx Corporation (NYSE:FDX), Amicus Therapeutics, Inc. (NASDAQ:FOLD),...
Jan 07, 2019 07:00 am ET
Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today provided unaudited preliminary Galafold revenue for the full-year 2018 and...
Jan 03, 2019 04:01 pm ET
Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8,...
Jan 03, 2019 07:00 am ET
Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the initiation of a Phase 1/2 clinical study to evaluate the safety...
Dec 20, 2018 07:00 am ET
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the dosing of the first patient in a global phase 3 clinical study...
Dec 19, 2018 04:01 pm ET
Amicus Therapeutics Announces Executive Team Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that Daphne Quimi will be promoted to Chief Financial Officer,...
Dec 11, 2018 04:01 pm ET
Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® (Migalastat)
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that Galafold® (migalastat) was awarded the 2018 UK Prix Galien Medal...
Dec 04, 2018 07:35 am ET
Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Xencor, Inc. (NASDAQ:XNCR), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC),...
Nov 12, 2018 07:00 am ET
Amicus Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, Arizona on Wednesday, November...
Nov 05, 2018 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2018. The...
Oct 29, 2018 07:00 am ET
Amicus Therapeutics to Announce Third Quarter 2018 Financial Results on November 5, 2018
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 5, 2018 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2018. The...
Oct 25, 2018 09:25 am ET
Recent Analysis Shows PennyMac Mortgage Investment Trust, Amicus Therapeutics, Children's Place, PLDT, NanoString Technologies, and Worthington Industries Market Influences — Renewed Outlook, Key Driv
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PennyMac Mortgage Investment Trust (NYSE:PMT), Amicus Therapeutics,...
Oct 11, 2018 07:00 am ET
Amicus Therapeutics to Host Analyst Day 2018 Today in New York City
Amicus Therapeutics, Inc. (NASDAQ: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases will host its Analyst Day today, October 11, 2018, in New York City from 8:30...
Oct 08, 2018 07:00 am ET
Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
Amicus Therapeutics (Nasdaq: FOLD) today announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to pursue research and development of novel gene therapies for Pompe...
Oct 05, 2018 07:00 am ET
Amicus Therapeutics Announces Positive 18-Month Data in Pompe Disease Phase 1/2 Study at 23rd International Annual Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme...
Oct 02, 2018 07:00 am ET
Amicus Therapeutics Announces Presentation and Poster at the 23rd International Congress of the World Muscle Society
Amicus Therapeutics (Nasdaq:FOLD), today announced that an oral presentation and a poster highlighting its development program AT-GAA for Pompe disease will be included at the 23rd International Congress of the World Muscle Society, to be held...
Sep 26, 2018 07:00 am ET
Amicus Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Leerink Partners Roundtable Series: Rare Disease Oncology in New York, NY on...
Sep 25, 2018 07:55 am ET
Report: Exploring Fundamental Drivers Behind Ocean Power Technologies, Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, Fanhua, and Parsley Energy — New Horizons, Emerging Trends, an
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ocean Power Technologies, Inc. (NASDAQ:OPTT), Amicus Therapeutics, Inc....
Sep 20, 2018 06:00 am ET
Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
Amicus Therapeutics (Nasdaq: FOLD) today announced the signing of a definitive agreement in which Amicus Therapeutics will receive worldwide development and commercial rights for ten gene therapy programs developed at The Center for Gene Therapy at...
Sep 11, 2018 07:00 am ET
Amicus Therapeutics Announces Board Appointments
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the appointment of Lynn D. Bleil to its Board of Directors, effective...
Sep 10, 2018 07:00 am ET
Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program AT-GAA...
Aug 31, 2018 07:00 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018
Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at two investor conferences in September. Bradley Campbell, President and Chief Operating Officer, and Chip Baird, Chief Financial Officer, will present a corporate overview...
Aug 10, 2018 04:05 pm ET
FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Galafold™ (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with...
Aug 07, 2018 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2018. The...
Jul 31, 2018 07:40 am ET
Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Interpace Diagnostics Group, Inc....
Jul 31, 2018 07:30 am ET
Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2018. The call...
Jul 30, 2018 08:00 am ET
Research Report Identifies General Dynamics, General Motors, Amicus Therapeutics, Drive Shack, Zoe's Kitchen, and Vishay Intertechnology with Renewed Outlook — Fundamental Analysis, Calculating Forwar
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of General Dynamics Corporation (NYSE:GD), General Motors Company (NYSE:GM),...
Jun 26, 2018 04:05 pm ET
Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for...
Jun 08, 2018 07:00 am ET
Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of  the Company’s President and Chief...
Jun 01, 2018 07:00 am ET
Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 39th Annual Global Healthcare Conference in...
May 30, 2018 12:00 am ET
Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan
Amicus Therapeutics (Nasdaq:FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold® capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry...
May 09, 2018 07:30 am ET
Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Tuesday, May 15,...
May 08, 2018 07:00 am ET
Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced financial results for the first quarter ended March 31, 2018. The...
Apr 26, 2018 07:30 am ET
Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
CRANBURY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended...
Apr 17, 2018 07:30 am ET
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
CRANBURY, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is participating in several activities in April to honor Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to...
Apr 16, 2018 07:55 am ET
Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco — Future Expectations, Projections Moving into 2018
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), Rite Aid...
Mar 22, 2018 09:30 pm ET
Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
First Amicus Medicine and First Oral Precision Medicine for Fabry Patients with an Amenable Mutation in Japan
Mar 09, 2018 08:15 am ET
Research Report Identifies Rayonier, Gannett Co., CBIZ, Amicus Therapeutics, Iamgold, and Urban Outfitters with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rayonier Inc. (NYSE:RYN), Gannett Co., Inc....
Mar 05, 2018 07:30 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018
CRANBURY, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced upcoming presentations at two investor conferences in March.
Feb 28, 2018 07:00 am ET
Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
Galafold Expansion Continues with 360+ Fabry Patients Treated Today - on Track to Achieve FY18 Revenue Guidance of $75M-$85M
Feb 28, 2018 06:30 am ET
Amicus Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 8:30 AM Eastern Time.
Feb 27, 2018 04:01 pm ET
Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives to Change People’s Lives Living with Rare Diseases
Unique Volunteerism, Mentorship, Giving, Global Access and Advocacy Programs Under Long-term Healing Beyond Disease Initiatives
Feb 21, 2018 04:30 pm ET
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 19,354,839 shares in the offering at a price of...
Feb 21, 2018 07:30 am ET
Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
CRANBURY, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ended...
Feb 15, 2018 07:00 pm ET
Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are...
Feb 14, 2018 04:01 pm ET
Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting...
Feb 13, 2018 04:01 pm ET
Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
CRANBURY, N.J., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the LEERINK Partners 7th Annual Global Healthcare...
Feb 12, 2018 07:30 am ET
Feb 07, 2018 04:01 pm ET
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™
        Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Out to Month 12
Jan 29, 2018 07:30 am ET
Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
CRANBURY, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that the Common Drug Review (CDR) has posted the Canadian Drug Expert Committee (CDEC)’s positive recommendation of Galafold™ (migalastat) for listing with provincial drug formularies. CDEC...
Jan 22, 2018 04:01 pm ET
Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium™ 2018
CRANBURY, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced that two oral presentations and seven posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 14th Annual WORLDSymposium™ 2018, to...
Jan 17, 2018 04:01 pm ET
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Spain
CRANBURY, N.J. and MADRID, Spain, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Spain...
Jan 08, 2018 07:30 am ET
Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance
            310+ People with Fabry Disease Treated with Reimbursed Galafold® at YE17
Dec 21, 2017 07:30 am ET
Amicus Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco,...
Dec 14, 2017 07:30 am ET
Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
CRANBURY, N.J., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to request approval of the oral precision medicine migalastat HCl (“migalastat”) for the...
Nov 29, 2017 07:50 am ET
Analysis: Positioning to Benefit within Cummins, Macy's, Twenty-First Century Fox, Amicus Therapeutics, Crocs, and Rand Logistics — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 29, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cummins Inc. (NYSE:CMI), Macy's Inc...
Nov 08, 2017 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
260+ Fabry Patients on Reimbursed Galafold™ (Migalastat) and On Target to Reach 300 Patients by Year-End 2017 ...
Nov 08, 2017 07:00 am ET
Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
260+ Fabry Patients on Reimbursed Galafold™ (Migalastat) and On Target to Reach 300 Patients by Year-End 2017
Sep 21, 2017 07:30 am ET
U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease
CRANBURY, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the U.S. FDA has granted orphan drug designation to ATB200/AT2221 for the treatment of Pompe disease, an inherited lysosomal storage disorder caused by deficiency of an enzyme called acid alpha-glucosidase (GAA). This novel treatment paradigm consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake, co-administered with AT2221, a pharmacological chaperone....
Sep 20, 2017 04:01 pm ET
Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
CRANBURY, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on Wednesday, September 27, 2017 at 1:00 p.m. ET....
Aug 15, 2017 04:01 pm ET
Amicus Therapeutics Announces Approval for Galafold™ (Migalastat) for Treatment of Fabry Disease in Australia
First Amicus Medicine and First Oral Precision Medicine for Fabry Disease in Australia...
Aug 07, 2017 07:00 am ET
Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
            179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 – On Target to Reach 300 Patients by Year-End 2017...
Jul 18, 2017 07:30 am ET
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 2,755,102 shares of common stock. As a result, the Company issued a total of 21,122,449 shares in the offering at a price of $12.25 per share....
Jul 12, 2017 08:00 pm ET
Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 18,367,347 shares of its common stock at $12.25 per share. The gross proceeds from the offering to Amicus are expected to be $225 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus.  In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,755,102 shares ...
Jul 11, 2017 06:00 am ET
Jun 07, 2017 07:30 am ET
Amicus Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
CRANBURY, N.J., June 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 15, 2017 at 10:40 a.m. P.T....
May 09, 2017 07:30 am ET
Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
  100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU...
May 02, 2017 04:01 pm ET
Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
CRANBURY, N.J., May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2017....
Mar 08, 2017 04:01 pm ET
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy
CRANBURY, N.J. and MILAN, Italy, March 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (Ministero della Salute). Galafold is now reimbursed in Italy as a therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable...
Mar 02, 2017 07:30 am ET
Amicus Therapeutics to Present at Upcoming Investor Conferences
CRANBURY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that management will present at two upcoming investor conferences....
Mar 01, 2017 07:00 am ET
Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates
Growing Momentum for EU Galafold (Migalastat) Launch for Fabry Disease Tracking Toward 300 Patients by Year-End 2017...
Feb 27, 2017 08:00 am ET
Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in the United Kingdom
National Institute for Health and Care Excellence (NICE) Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease ...
Feb 22, 2017 05:36 pm ET
Amicus Therapeutics to Announce Full-Year 2016 Financial Results and Corporate Updates on March 1, 2017
CRANBURY, N.J., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Wednesday, March 1, 2017 at 8:30 a.m. ET to discuss financial results for the year ended December 31, 2016....
Feb 15, 2017 07:30 pm ET
Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients...
Feb 14, 2017 07:30 pm ET
Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium™ 2017
New Phase 3 Retrospective Analysis Shows Correlation between Reduction in Disease Substrate (Kidney Interstitial Capillary GL-3) and Improved Diarrhea in Fabry Patients with Amenable Mutations treated with Migalastat...
Feb 06, 2017 08:45 am ET
The Biotech Market Grows as Demand for New Therapeutics Increases
NEW YORK, February 6, 2017 /PRNewswire/ --...
Jan 24, 2017 07:30 am ET
Amicus Therapeutics Announces Presentations and Posters at 13th Annual WORLDSymposium™ 2017
CRANBURY, N.J., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3 oral presentations and 9 posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 13th Annual WORLDSymposium™ 2017, to be held February 13-17, 2017 in San Diego, CA....
Dec 21, 2016 04:01 pm ET
Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full of Option to Purchase Additional Notes
CRANBURY, N.J., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announced the closing of its previously announced private offering of $250 million aggregate principal amount of 3.00% convertible senior notes due 2023 (the “notes”), including the full exercise by the initial purchasers of their option to purchase up to an additional $25 million aggregate principal amount of notes on the same terms and conditions, solely to cover over-allotments.  Amicus anticipates that the aggregate net proc...
Dec 15, 2016 08:45 pm ET
Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes
CRANBURY, N.J., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that it has priced its previously announced private offering of $225 million aggregate principal amount of 3.00% convertible senior notes due 2023 (the “notes”) in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Amicus has granted the initial purchasers an option, exercisable for 30 days, to purchase up to an additional $25 million aggregate principal amount of notes on the ...
Dec 14, 2016 04:01 pm ET
Amicus Therapeutics Announces Proposed Offering of Convertible Senior Notes
CRANBURY, N.J., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, announced today that it intends to offer $225,000,000 aggregate principal amount of convertible senior notes due 2023 (the “notes”) in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Amicus intends to grant the initial purchasers an option, exercisable for 30 days, to purchase up to an additional $25 million aggregate principal amount of notes on the same terms and conditions, solely to cover...
Dec 01, 2016 11:42 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amicus Therapeutics, Inc. - FOLD
NEW YORK, Dec. 1, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Nov 29, 2016 04:44 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amicus Therapeutics, Inc. (FOLD)
NEW YORK, Nov. 29, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/fold. ...
Nov 28, 2016 04:09 pm ET
Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease
Regulatory Plan for Full Approval Pathway Based on Generation of Additional Gastrointestinal Symptoms Data...
Nov 01, 2016 07:30 am ET
Amicus Therapeutics to Announce Third Quarter 2016 Financial Results on November 7, 2016
CRANBURY, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Monday, November 7, 2016 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2016....
Sep 22, 2016 07:30 am ET
Amicus Therapeutics to Present at LEERINK Roundtable Series: Rare Disease & Immuno-Oncology
CRANBURY, N.J., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on September 28, 2016 at 3:05pm ET....
Sep 13, 2016 11:51 am ET
UPDATE -- Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016
CRANBURY, N.J., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on September 14, 2016 in London, UK at 9:45am UTC (5:45am ET)....
Sep 12, 2016 07:30 am ET
Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016
CRANBURY, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on September 14, 2016 in London, UK at 1:45pm UTC (8:45am ET)....
Sep 01, 2016 07:30 am ET
Amicus Therapeutics to Present at Robert W. Baird & Co. 2016 Healthcare Conference
CRANBURY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in New York, NY on Wednesday, September 7 at 3:10pm ET....
Aug 31, 2016 07:30 am ET
Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
CRANBURY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that 7 posters highlighting its Fabry program will be included in the Society for the Study of Inborn Errors of Metabolism’s 2016 SSIEM Annual Symposium to be held September 6-9, 2016 in Rome, Italy....
Aug 10, 2016 06:05 pm ET
UPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
CRANBURY, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the August 11 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com....
Aug 10, 2016 05:18 pm ET
New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
CRANBURY, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the June 9 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com....
Aug 03, 2016 07:30 am ET
Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
         Pre-Submission Meeting Completed with Pharmaceuticals and Medical Devices Agency (PMDA) in Japan...
Aug 01, 2016 04:01 pm ET
Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016
CRANBURY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2016....
Jul 12, 2016 07:30 am ET
Amicus Therapeutics Appoints Former FDA Division Deputy Director Andrew Mulberg as Vice President, Regulatory Strategy
     Former Deputy Director of FDA Division of Gastroenterology and Inborn Errors Products...
Jul 06, 2016 04:01 pm ET
Amicus Therapeutics Expands Biologics Pipeline with New Preclinical Program for Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency
CRANBURY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare and devastating genetic neurological disease for which there is no currently approved treatment. Signs and symptoms typically begin with persistent, spontaneous seizures in infancy followed by severe delays in neurological development....
Jun 10, 2016 07:30 am ET
Amicus Therapeutics Appoints Craig A. Wheeler to Board of Directors
CRANBURY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders....
Jun 01, 2016 07:30 am ET
Amicus Therapeutics to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
CRANBURY, N.J., June 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7, 2016 at 2:40 p.m. PT....
May 05, 2016 07:30 am ET
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
CRANBURY, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wednesday, May 11, 2016 at 4:20 p.m. PT....
Mar 03, 2016 09:31 am ET
Covered Call Alerts For Bank of America, Twitter, Inovio Pharmaceuticals, Marathon Oil Corporation and Amicus Therapeutics Released By InvestorsObserver
CHICAGO, March 3, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, TWTR, INO, MRO and FOLD....